Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Optimal application of PD-L1 IHC tests

Emina E. Torlakovic • 12 Apr 2021
AACR 2021
General

Emina E. Torlakovic, PhD, MD, FCAP, University of Saskatchewan, Saskatoon, Canada, discusses the optimal use of PD-L1 immunohistochemistry (IHC) tests, suggesting high value in the early stages of clinical trial design when biomarkers have not yet been defined. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

More from Emina E. Torlakovic

Analysis and comparison of PD-L1 IHC tests
4:05
Analysis and comparison of PD-L1 IHC tests
Emina E. Torlakovic • 12 Apr 2021

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The content of VJOncology is intended for healthcare professionals